Prostate cancer (PC) is the most commonly diagnosed malignancy among males worldwide. In recent years, there has been a need to find alternative methods for the early diagnosis of PC. Evidence indicates that metabolic dysfunction is a characteristic feature of PC carcinogenesis, with various metabolites acting as biomarkers of tumor growth. Metabolomics is a new science that has emerged at the intersection of molecular biology, biochemistry, and genetics. The complete set of substrates and metabolic products is a metabolic profile, or metabolome. The PC metabolome comprises substances formed as a result of metabolic changes in response to the occurrence of a malignant process in the prostate gland. We have obtained unique data on metabolic changes that allow us to rethink the carcinogenesis of PC. Research on the metabolome opens up new opportunities for the early diagnosis and treatment of PC, with implications for its prognosis.

Prostate cancer (PC) is the most commonly diagnosed malignancy among males worldwide. In recent years, there has been a need to find alternative methods for the early diagnosis of PC. Evidence indicates that metabolic dysfunction is a characteristic feature of PC carcinogenesis, with various metabolites acting as biomarkers of tumor growth. Metabolomics is a new science that has emerged at the intersection of molecular biology, biochemistry, and genetics. The complete set of substrates and metabolic products is a metabolic profile, or metabolome. The PC metabolome comprises substances formed as a result of metabolic changes in response to the occurrence of a malignant process in the prostate gland. We have obtained unique data on metabolic changes that allow us to rethink the carcinogenesis of PC. Research on the metabolome opens up new opportunities for the early diagnosis and treatment of PC, with implications for its prognosis.

Prostate cancer (PC) is the most commonly diagnosed malignancy among males worldwide. In recent years, there has been a need to find alternative methods for the early diagnosis of PC. Evidence indicates that metabolic dysfunction is a characteristic feature of PC carcinogenesis, with various metabolites acting as biomarkers of tumor growth. Metabolomics is a new science that has emerged at the intersection of molecular biology, biochemistry, and genetics. The complete set of substrates and metabolic products is a metabolic profile, or metabolome. The PC metabolome comprises substances formed as a result of metabolic changes in response to the occurrence of a malignant process in the prostate gland. We have obtained unique data on metabolic changes that allow us to rethink the carcinogenesis of PC. Research on the metabolome opens up new opportunities for the early diagnosis and treatment of PC, with implications for its prognosis.

Prostate cancer (PC) is the most commonly diagnosed malignancy among males worldwide. In recent years, there has been a need to find alternative methods for the early diagnosis of PC. Evidence indicates that metabolic dysfunction is a characteristic feature of PC carcinogenesis, with various metabolites acting as biomarkers of tumor growth. Metabolomics is a new science that has emerged at the intersection of molecular biology, biochemistry, and genetics. The complete set of substrates and metabolic products is a metabolic profile, or metabolome. The PC metabolome comprises substances formed as a result of metabolic changes in response to the occurrence of a malignant process in the prostate gland. We have obtained unique data on metabolic changes that allow us to rethink the carcinogenesis of PC. Research on the metabolome opens up new opportunities for the early diagnosis and treatment of PC, with implications for its prognosis.

Collectively migrating tumor cells have been recently implicated in enhanced metastasis of epithelial malignancies. In oral squamous cell carcinoma (OSCC), v integrin is a crucial mediator of multicellular clustering and collective movement ; however, its contribution to metastatic spread remains to be addressed. According to the emerging therapeutic concept, dissociation of tumor clusters into single cells could significantly suppress metastasis-seeding ability of carcinomas. This study aimed to investigate the anti-OSCC potential of novel endostatin-derived polypeptide PEP06 as a cluster-dissociating therapeutic agent . Firstly, we found marked enrichment of v integrin in collectively invading multicellular clusters in human OSCCs. Our study revealed that metastatic progression of OSCC was associated with augmented immunostaining of v integrin in cancerous lesions. Following PEP06 treatment, cell clustering on fibronectin, migration, multicellular aggregation, anchorage-independent survival and colony formation of OSCC were significantly inhibited. Moreover, PEP06 suppressed v integrin/FAK/Src signaling in OSCC cells. PEP06-induced loss of active Src and E-cadherin from cell-cell contacts contributed to diminished collective migration of OSCC . Overall, these results suggest that PEP06 polypeptide 30 inhibiting v integrin/FAK/Src signaling and disrupting E-cadherin-based intercellular junctions possesses anti-metastatic potential in OSCC by acting as a cluster-dissociating therapeutic agent.